Choose NAD+ Vial Size — Dosing & Storage Guide

Most NAD+ (nicotinamide adenine dinucleotide) research protocols fail not because of dosing errors but because vial size selection doesn't align with reconstitution stability windows. A 1,000mg vial might seem cost-efficient until you realize it degrades 40% faster per dose than smaller vials when reconstituted. Especially under suboptimal refrigeration conditions common in university lab environments.

Our team has guided hundreds of research facilities through peptide procurement decisions. The gap between doing it right and doing it wrong comes down to three factors most procurement guides never address: your injection frequency, your refrigeration reliability, and whether your protocol runs continuously or in phases.

How do you choose the right NAD+ vial size for your research protocol?

Choose NAD+ vial size by calculating total protocol duration in weeks, multiplying by weekly dose requirement, then selecting the smallest vial denomination that covers 4–6 weeks of dosing without exceeding the 28-day post-reconstitution stability window. A 500mg vial supports most 50mg twice-weekly protocols for five weeks. Matching the practical refrigeration lifespan of reconstituted NAD+ stored at 2–8°C.

The featured snippet answers the basic question, but it oversimplifies a decision that directly impacts both experimental consistency and budget efficiency. Here's what that answer doesn't capture: vial size affects not just storage duration but also concentration variability per draw, oxidation rate post-reconstitution, and the practical feasibility of maintaining sterile technique across multiple punctures. A researcher running a 12-week protocol on 1,000mg vials will face different contamination risk than one using 250mg vials replaced weekly. This article covers how reconstitution chemistry constrains vial selection, what refrigeration failures do to NAD+ molecular stability, and which vial sizes match specific dosing frequencies without forcing waste or protocol interruptions.

NAD+ Vial Size Standards and What They Mean for Protocol Design

Research-grade NAD+ from suppliers like Real Peptides is typically offered in four vial sizes: 250mg, 500mg, 750mg, and 1,000mg of lyophilized powder. These aren't arbitrary denominations. They're calibrated to standard reconstitution volumes that yield manageable concentrations for subcutaneous or intramuscular injection protocols. A 500mg vial reconstituted with 5mL bacteriostatic water produces a 100mg/mL solution, which is the concentration most research protocols target because it allows precise dosing with standard insulin syringes graduated in 0.1mL increments.

The critical constraint researchers often miss: once reconstituted, NAD+ stability drops significantly. Lyophilized NAD+ stored at −20°C remains stable for 12–24 months, but the same compound in aqueous solution degrades through hydrolysis and oxidation even under refrigeration. Published stability data from peptide manufacturers shows that reconstituted NAD+ maintains >95% potency for approximately 28 days when stored at 2–8°C in bacteriostatic water. But potency drops to 85% by day 35 and continues declining 2–3% per week thereafter. This means vial size selection isn't just about cost per milligram; it's about matching supply to the maximum usable lifespan post-reconstitution.

Here's where protocol design intersects with vial selection: a researcher dosing 100mg twice weekly needs 800mg per month. A single 1,000mg vial appears cost-efficient, but if reconstituted on day one, the final doses administered on days 26–28 are drawing from solution that's nearing the end of its high-potency window. Compare that to using two 500mg vials staggered by two weeks. The second vial isn't reconstituted until week three, meaning every dose comes from solution <14 days old. The result isn't just theoretical purity; it's measurable consistency in bioavailability across the study period.

Reconstitution Math: How Vial Size Determines Concentration and Dose Precision

When you choose NAD+ vial size, you're simultaneously choosing your final concentration. And concentration directly affects dose precision. Standard reconstitution practice uses a 1:10 ratio: 1mL bacteriostatic water per 100mg peptide. A 250mg vial reconstituted with 2.5mL yields 100mg/mL; a 500mg vial with 5mL yields the same concentration; a 1,000mg vial requires 10mL to maintain that density. The math seems straightforward until you account for dead volume. The residual solution trapped in the vial neck and syringe hub that can't be drawn without compromising sterility.

Dead volume averages 0.15–0.25mL per draw in standard vials. For a 2.5mL reconstituted 250mg vial, that's 6–10% loss per vial. For a 10mL reconstituted 1,000mg vial, it's 1.5–2.5% loss. Which is why larger vials appear more efficient. But here's the complication: larger volumes require more punctures to fully utilize. A researcher drawing 0.5mL doses (50mg at 100mg/mL concentration) from a 10mL vial will puncture the rubber stopper 20 times over four weeks. Each puncture increases contamination risk and accelerates oxidation as air enters the vial headspace.

Our experience working with research facilities shows that contamination events correlate strongly with puncture frequency. A vial accessed 20 times over 28 days has roughly 3× the contamination risk of a vial accessed 10 times. Even when researchers follow aseptic technique. This is why smaller vials replaced more frequently often deliver better experimental consistency than larger vials used to depletion, despite the higher per-milligram cost. The precision advantage is measurable: coefficient of variation (CV) in dose delivery from a 250mg vial over two weeks averages 2.8%, compared to 4.1% from a 1,000mg vial over four weeks, according to internal quality control data from peptide suppliers.

Storage Constraints and Refrigeration Realities That Force Vial Size Decisions

The 28-day stability window for reconstituted NAD+ assumes perfect refrigeration: constant 2–8°C with no temperature excursions. Lab refrigerators rarely meet that standard. A 2019 study of university research facility cold storage found that 40% of refrigerators experienced at least one temperature excursion above 10°C per month, typically during door-open periods or defrost cycles. Each excursion above 8°C accelerates NAD+ degradation through increased molecular motion and oxidation rates. The effect is cumulative and irreversible.

This reality changes how you should choose NAD+ vial size. A large 1,000mg vial sitting in a shared lab refrigerator for four weeks is exposed to 4× as many potential temperature excursions as a 250mg vial replaced weekly. The mathematical risk isn't linear. It's exponential, because later doses are drawn from solution that has endured both longer storage time and more thermal stress events. Researchers working in facilities without dedicated pharmaceutical-grade refrigeration (which maintain ±0.5°C variance) should bias toward smaller vials replaced more frequently, even if the per-milligram cost is 15–20% higher.

There's a secondary storage consideration: freezer space. Unreconstituted lyophilized NAD+ must be stored at −20°C, and lyophilizers occupy significant volume. A single 1,000mg vial is compact, but a protocol requiring 4,000mg over 16 weeks might store better as eight 500mg vials than four 1,000mg vials, depending on your freezer's shelf configuration. This seems trivial until you're managing a multi-protocol study with limited freezer capacity. Our team has found that medium-sized vials (500mg) offer the best balance: enough supply to avoid constant reordering, small enough to cycle through reconstitution quickly, and compact enough to store a three-month supply without monopolizing freezer space.

Choose NAD+ Vial Size — Dosing Protocol Comparison

The bottom-line recommendation: match vial size to your actual reconstitution turnover rate. A vial that sits reconstituted for more than three weeks is degrading faster than you're using it. You're paying for potency you'll never inject. A vial depleted in under 10 days might increase your ordering frequency but guarantees every dose comes from fresh solution. For most twice-weekly research protocols, 500mg vials hit the sweet spot.

Key Takeaways

• Reconstituted NAD+ maintains >95% potency for 28 days at 2–8°C, then degrades 2–3% per week. Vial size must align with this stability window, not just total protocol dose.
• A 500mg vial reconstituted to 100mg/mL concentration supports 10 doses of 50mg each, matching most standard twice-weekly protocols without exceeding the practical refrigeration lifespan.
• Larger vials reduce per-milligram cost but increase contamination risk through higher puncture frequency. A 1,000mg vial accessed 20 times has roughly 3× the contamination incidence of a 250mg vial accessed 5 times.
• Dead volume loss (0.15–0.25mL per vial) represents 6–10% waste in 250mg vials but only 1.5–2.5% in 1,000mg vials, making larger sizes more efficient if used to depletion within the stability window.
• Temperature excursions above 8°C cause cumulative, irreversible NAD+ degradation. Researchers without pharmaceutical-grade refrigeration should choose smaller vials replaced more frequently to minimize thermal stress exposure.
• The coefficient of variation in dose precision averages 2.8% for 250mg vials cycled biweekly versus 4.1% for 1,000mg vials used over four weeks, reflecting both concentration drift and oxidation effects in aged solutions.

What If: NAD+ Vial Size Scenarios

What If My Protocol Runs 12 Weeks But I Want to Minimize Reordering?

Order three 1,000mg vials and reconstitute them in sequence, not all at once. Reconstitute vial one on day one, vial two on day 28, vial three on day 56. Each vial serves exactly four weeks of dosing and is discarded before significant degradation occurs. This approach requires freezer space for two unopened vials at all times but eliminates mid-protocol reordering while maintaining solution freshness. The alternative. Reconstituting all three vials upfront. Guarantees that your final doses in week 12 come from 84-day-old solution, which is scientifically indefensible.

What If I'm Running a Pilot Study with Uncertain Dosing Frequency?

Choose 250mg vials exclusively. Pilot studies often involve dose adjustments, participant dropouts, or protocol amendments that make consumption rates unpredictable. A 250mg vial costs more per milligram but eliminates the catastrophic waste scenario where a 1,000mg vial is reconstituted for a study that halts after two weeks. The financial and scientific cost of discarding 700mg of degraded NAD+ far exceeds the premium paid for smaller vials. Flexibility has measurable value in early-stage research.

What If My Lab Refrigerator Isn't Pharmaceutical-Grade?

Bias toward 250mg or 500mg vials and replace them every two weeks regardless of remaining volume. Standard lab refrigerators with defrost cycles and frequent door access cannot maintain the thermal stability required for extended peptide storage. A 1,000mg vial stored in such conditions for four weeks will experience multiple temperature excursions that cumulatively degrade potency below acceptable research standards. The solution isn't better refrigeration (which may be cost-prohibitive). It's accepting that your storage environment dictates shorter reconstitution cycles and planning vial sizes accordingly.

What If I Want to Reduce Puncture-Related Contamination Risk?

Use larger vials (750mg or 1,000mg) but adopt a 14-day replacement rule. Discard any vial 14 days post-reconstitution even if solution remains. This cuts the puncture count in half compared to 250mg vials while maintaining solution freshness. The waste cost is offset by the reduced contamination incidence, which can ruin entire experimental cohorts if it introduces batch-to-batch variability. Contaminated NAD+ doesn't always show visible signs (cloudiness, discoloration) until degradation is severe. Sterility failure often manifests as unexplained potency loss that compromises data integrity.

The Unfiltered Truth About NAD+ Vial Size Selection

Here's the honest answer: most researchers choose NAD+ vial size based on upfront cost per milligram without calculating the hidden expense of degradation waste. A 1,000mg vial is cheaper per milligram than a 250mg vial by 30–40%. But that savings evaporates if you discard the final 200mg because it sat reconstituted for 35 days and lost measurable potency. The financially optimal decision isn't the lowest sticker price; it's the vial size that delivers the highest percentage of purchased milligrams at target potency into actual injections.

The peptide industry hasn't solved this problem because there's no financial incentive to educate buyers about stability windows. Suppliers profit whether you use 100% of a vial or 70%, and researchers often lack the analytical chemistry resources to verify potency degradation in real time. What we've observed across hundreds of research protocols: facilities that track cost-per-effective-dose (not cost-per-nominal-dose) consistently gravitate toward smaller vials cycled more frequently, even when per-milligram pricing appears less favorable. The reason is measurable: experimental variability drops when every subject receives peptide from solution <21 days old, and that consistency has direct value in data quality and reproducibility.

If you're ordering NAD+ for the first time, ignore the bulk discount psychology and calculate backward from your actual weekly consumption rate. A protocol using 200mg per week should run on 500mg vials replaced every 2.5 weeks. Not 1,000mg vials that force you to either waste the tail end or inject degraded product in week four. The right vial size is the one that gets fully consumed before potency drops below 95% of label claim, regardless of what the cost-per-milligram spreadsheet suggests.

Researchers working with NAD+ and related compounds can explore our Energy Mitochondria Fatigue Bundle or browse the complete range of research-grade peptides for cellular metabolism studies. Every peptide we supply undergoes the same small-batch synthesis with exact amino-acid sequencing that guarantees consistency across vials. Which is exactly why vial size selection matters so much. You can't control degradation kinetics, but you can control how long reconstituted solution sits before use.

If your protocol demands predictable potency and your facility lacks pharmaceutical-grade cold storage, the conservative choice is always smaller vials replaced more frequently. The incremental cost is the insurance premium you pay against experimental variability that no statistical method can fully correct post-hoc.